Advertisement

Neurological Disorder Identified As Unusual Side Effect Of AstraZeneca's Jab

The EMA advised that material on the vaccine should include a warning that patients should seek medical assistance if they develop weakness and paralysis in their limbs, which can proceed to their chest and face.

According to the European Medicines Agency(EMA), the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, has been identified as an extremely unusual side effect of the AstraZeneca COVID-19 vaccine.

The EMA said in an update Wednesday that a causal association was considered at least a reasonable possibility after 833 cases of the syndrome were recorded worldwide by 31st July from around 592 million doses of the AstraZeneca 'Vaxzevria' shot administered.

The Amsterdam-based agency stated, “GBS should therefore be added to the product information as a side effect of Vaxzevria.”

Less than one in 10,000 persons suffer from Guillain-Barre Syndrome. Symptoms include transient paralysis and respiratory difficulties, as well as a nerve irritation. About 3,000 to 6,000 Americans are affected by this exceedingly unusual syndrome each year and the majority of them recover.

The EMA advised that material on the vaccine should include a warning that patients should seek medical assistance if they develop weakness and paralysis in their limbs, which can proceed to their chest and face.

Johnson & Johnson vaccine, which also employs the AstraZeneca vaccine's adenovirus technology, was categorised as having extremely unusual side effects by the European Medicines Agency in July.

Also in July, the US Food and Drug Administration warned of a increased risk of getting a neurological condition from Johnson & Johnson's dose.

Both the regulators agreed that the vaccine's advantages outweighed its hazards.



Advertisement

Around The World